By Topic
CETTIRE's (ASX: CTT) share price is back to all time low levels, is it time to buy?
Recent tariff changes and trade frictions have disrupted that advantage and slowed growth. However, CETTIRE’s flexible, low-cost structure suggests its core model remains intact, leaving the company with meaningful long-term profit potential despite the current uncertainty around customer growth and demand.
Meeka Metals (ASX: MEK) Tests Major Support: Can the Downtrend Stabilise?
Meeka Metals faces selling pressure near key support after a volatile year, amid operational challenges and cautious sentiment. As it transitions to production at Murchison, investors are watching whether support holds or signals further downside despite long-term growth potential.
What is the reason for the plummet in Dimerix (ASX: DXB) share price, and how much lower can it go?
Dimerix shares plunged 35–40% amid heavy selling and uncertainty around clinical updates, worsened by weak biotech sentiment. Further downside depends on results and the funding outlook, though volatility in early-stage biotech stocks suggests a potential for sharp rebounds.
Lumos Diagnostics (ASX: LDX) Shares Keep Sliding Despite Last Year’s Rally
Lumos Diagnostics shares have dropped sharply after last year’s rally, with weak technical signals and dilution concerns weighing on sentiment. Despite long-term optimism around FebriDx and US commercialisation, investors remain cautious due to slow revenue growth and ongoing funding pressures.
Has Neurizon Therapeutics (ASX: NUZ) Formed a Sustainable Long-Term Floor at Its Multi-Year Support Base?
Neurizon Therapeutics (ASX: NUZ) is a clinical-stage biotech developing NUZ-001 for ALS and other neurodegenerative diseases. Despite promising data and global trials, the stock faces pressure from clinical delays, dilution, rising losses, and ongoing uncertainty typical of pre-revenue biotech companies.
Telix Pharmaceuticals (ASX: TLX) Rebounds From Heavy Sell-Off Reignites Investor Optimism
Telix Pharmaceuticals (ASX: TLX) is recovering after a sharp biotech sell-off driven by regulatory and legal concerns. Renewed investor confidence follows strong revenue growth, progress in Phase 3, and a Regeneron partnership, with FY2026 revenue nearing US$1 billion and pipeline milestones advancing.
...